Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02590939 · ClinicalTrials.gov registry record · NA
Acute Treatment of Migraine With e-TNS
A NA study, sponsored by Cefaly Technology.
- Completed
- Registry status
- NA
- Development phase
- 106
- Enrollment target
NCT02590939: Completed NA study, sponsored by Cefaly Technology.
NCT02590939 is a NA study that has completed, run by Cefaly Technology. The registered enrollment target is 106 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02590939, a NA study, has completed, sponsored by Cefaly Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 106 participants
- Enrollment target
Study Summary
The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients. The patients will be applied either an active or placebo external neurostimulation for 1 hour during a migraine attack, and will report the pain on a visual analog scale before and after the treatment.
Primary Outcome
Mean change of pain score (measured on a pain visual analog scale containing 11 values, from 0 to 10, with 0 meaning no pain and 10 meaning maximal pain) at 1 hour compared to baseline
Interventions
- DEVICE CEFALY Active
- DEVICE CEFALY Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2017-03-31 |
| Phase | NA |
What the finished NCT02590939 record still lists
NCT02590939 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which CEFALY Active is the first listed.
NCT02590939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02590939 about?
NCT02590939 is a clinical study titled "Acute Treatment of Migraine With e-TNS". The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients. The patients will be applied either an active or placebo external neurostimulation for 1 hour during a migraine attack, and will report the pain on a visual an...
What is the current status of trial NCT02590939?
This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2016-02-01. Estimated completion is 2017-03-31.
What interventions are being tested in trial NCT02590939?
The interventions under investigation include: CEFALY Active (DEVICE), CEFALY Placebo (DEVICE).
Who is sponsoring clinical trial NCT02590939?
This trial is sponsored by Cefaly Technology, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02590939's enrollment target sits among peer trials
106 830th of 2000 higher than 1,167 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI